177 related articles for article (PubMed ID: 35315249)
1. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
Arthritis Rheumatol; 2022 May; 74(5):735-751. PubMed ID: 35315249
[TBL] [Abstract][Full Text] [Related]
2. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
[TBL] [Abstract][Full Text] [Related]
4. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
[TBL] [Abstract][Full Text] [Related]
5. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron K; Benseler S; Berard RA; Broderick L; Dedeoglu F; Diebold M; Durrant K; Ferguson P; Foell D; Hausmann JS; Jones OY; Kastner D; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman HM; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
Arthritis Rheumatol; 2022 Jul; 74(7):1102-1121. PubMed ID: 35621220
[TBL] [Abstract][Full Text] [Related]
6. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron KS; Benseler S; Berard R; Broderick L; Dedeoglu F; Diebold M; Durrant KL; Ferguson P; Foell D; Hausmann J; Jones OY; Kastner DL; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman H; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
Ann Rheum Dis; 2022 Jul; 81(7):907-921. PubMed ID: 35623638
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
Front Immunol; 2022; 13():825367. PubMed ID: 35418997
[TBL] [Abstract][Full Text] [Related]
8. [Type I interferonopathies].
Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
[TBL] [Abstract][Full Text] [Related]
9. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
Kim H; Sanchez GA; Goldbach-Mansky R
J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics of 25 patients with type Ⅰ interferonopathies].
Wang W; Wang W; Zou LP; He TY; Ma MS; Li WD; Yu ZX; Yang J; Song HM
Zhonghua Er Ke Za Zhi; 2021 Dec; 59(12):1043-1047. PubMed ID: 34856663
[No Abstract] [Full Text] [Related]
11. Type I interferonopathies in pediatric rheumatology.
Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
[TBL] [Abstract][Full Text] [Related]
12. STING palmitoylation as a therapeutic target.
Hansen AL; Mukai K; Schopfer FJ; Taguchi T; Holm CK
Cell Mol Immunol; 2019 Mar; 16(3):236-241. PubMed ID: 30796349
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
[TBL] [Abstract][Full Text] [Related]
14. Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS).
Papendorf JJ; Ebstein F; Alehashemi S; Piotto DGP; Kozlova A; Terreri MT; Shcherbina A; Rastegar A; Rodrigues M; Pereira R; Park S; Lin B; Uss K; Möller S; da Silva Pina AF; Sztajnbok F; Torreggiani S; Niemela J; Stoddard J; Rosenzweig SD; Oler AJ; McNinch C; de Guzman MM; Fonseca A; Micheloni N; Fraga MM; Perazzio SF; Goldbach-Mansky R; de Jesus AA; Krüger E
Front Immunol; 2023; 14():1190104. PubMed ID: 37600812
[TBL] [Abstract][Full Text] [Related]
15. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
16. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
Yu ZX; Song HM
World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
[TBL] [Abstract][Full Text] [Related]
17. Genetic interferonopathies: An overview.
Eleftheriou D; Brogan PA
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
[TBL] [Abstract][Full Text] [Related]
18. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
de Jesus AA; Hou Y; Brooks S; Malle L; Biancotto A; Huang Y; Calvo KR; Marrero B; Moir S; Oler AJ; Deng Z; Montealegre Sanchez GA; Ahmed A; Allenspach E; Arabshahi B; Behrens E; Benseler S; Bezrodnik L; Bout-Tabaku S; Brescia AC; Brown D; Burnham JM; Caldirola MS; Carrasco R; Chan AY; Cimaz R; Dancey P; Dare J; DeGuzman M; Dimitriades V; Ferguson I; Ferguson P; Finn L; Gattorno M; Grom AA; Hanson EP; Hashkes PJ; Hedrich CM; Herzog R; Horneff G; Jerath R; Kessler E; Kim H; Kingsbury DJ; Laxer RM; Lee PY; Lee-Kirsch MA; Lewandowski L; Li S; Lilleby V; Mammadova V; Moorthy LN; Nasrullayeva G; O'Neil KM; Onel K; Ozen S; Pan N; Pillet P; Piotto DG; Punaro MG; Reiff A; Reinhardt A; Rider LG; Rivas-Chacon R; Ronis T; Rösen-Wolff A; Roth J; Ruth NM; Rygg M; Schmeling H; Schulert G; Scott C; Seminario G; Shulman A; Sivaraman V; Son MB; Stepanovskiy Y; Stringer E; Taber S; Terreri MT; Tifft C; Torgerson T; Tosi L; Van Royen-Kerkhof A; Wampler Muskardin T; Canna SW; Goldbach-Mansky R
J Clin Invest; 2020 Apr; 130(4):1669-1682. PubMed ID: 31874111
[TBL] [Abstract][Full Text] [Related]
19. Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management.
McDermott A; Jacks J; Kessler M; Emanuel PD; Gao L
Int J Dermatol; 2015 Feb; 54(2):121-9. PubMed ID: 25521013
[TBL] [Abstract][Full Text] [Related]
20. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling.
Hansen AL; Buchan GJ; Rühl M; Mukai K; Salvatore SR; Ogawa E; Andersen SD; Iversen MB; Thielke AL; Gunderstofte C; Motwani M; Møller CT; Jakobsen AS; Fitzgerald KA; Roos J; Lin R; Maier TJ; Goldbach-Mansky R; Miner CA; Qian W; Miner JJ; Rigby RE; Rehwinkel J; Jakobsen MR; Arai H; Taguchi T; Schopfer FJ; Olagnier D; Holm CK
Proc Natl Acad Sci U S A; 2018 Aug; 115(33):E7768-E7775. PubMed ID: 30061387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
